Introduction
============

Lung cancer is the most common malignancy diagnosed in males, and the fourth most common diagnosed malignancy in females worldwide. Moreover, it is the leading cause of cancer-related mortality in males and the second leading cause of cancer-related death in females. Based on the GLOBOCAN 2008 estimates, lung cancer accounts for 13% (1.6 million) of the total cases and 18% (1.4 million) of deaths in 2008 ([@b1-etm-04-04-0569]). Lung cancer is a complex, multistage and multifactor disease. Smoking and environmental or occupational exposure may increase the risk of lung cancer; inherited polymorphisms including carcinogen metabolism ([@b2-etm-04-04-0569]), DNA damage and repair capacity ([@b3-etm-04-04-0569]), cell apoptosis ([@b4-etm-04-04-0569]) and cell-cycle control ([@b5-etm-04-04-0569]) also play important roles in determining interindividual variations in lung cancer susceptibility.

The murine double minute 2 (*MDM2*) gene located on chromosome 12q13--14 encodes an important negative regulator for the p53 tumor suppressor, resulting in its ubiquitination by direct binding to p53 ([@b6-etm-04-04-0569]). Apart from this critical function, *MDM2* overexpression may inhibit DNA repair independent of p53 ([@b7-etm-04-04-0569],[@b8-etm-04-04-0569]). The carcinogenesis of *MDM2* overexpression has been observed in various human tumors including lung ([@b9-etm-04-04-0569]--[@b11-etm-04-04-0569]), breast ([@b12-etm-04-04-0569]), bladder ([@b13-etm-04-04-0569]), gastric ([@b14-etm-04-04-0569]) and colorectal cancers ([@b15-etm-04-04-0569]).

An SNP (SNP309, T to G change at nucleotide 309) in the first intron of the *MDM2* gene was identified and was found to be associated with an increased affinity for binding stimulatory protein SP1 to the promoter region, resulting in increased *MDM2* gene transcription and attenuation of the p53 pathway ([@b16-etm-04-04-0569]). Subsequently, several molecular epidemiological studies were conducted to assess the association between *MDM2* SNP309 and lung cancer risk in Asians ([@b10-etm-04-04-0569],[@b17-etm-04-04-0569]--[@b19-etm-04-04-0569]) Caucasians ([@b9-etm-04-04-0569],[@b20-etm-04-04-0569]--[@b22-etm-04-04-0569]) and African-Americans ([@b11-etm-04-04-0569]). However, the results were not always consistent, possibly attributable to the fact that the majority of studies featured only a small number of samples or the association between the *MDM2* SNP309 polymorphism and lung cancer risk did not achieve statistical significance. Two meta-analyses published in 2009 exploring the *MDM2* SNP309 polymorphism and lung cancer risk yielded contradictory results ([@b23-etm-04-04-0569],[@b24-etm-04-04-0569]) and other two meta-analyses investigating *MDM2* SNP309 and tumor susceptibility published in 2011 also showed inconsistent results ([@b25-etm-04-04-0569],[@b26-etm-04-04-0569]). To resolve these inconsistencies, we conducted the present meta-analysis of available case-control studies investigating the association between *MDM2* SNP309 and lung cancer risk using METAGEN ([@b27-etm-04-04-0569]). In addition to performing subgroup analyses based on ethnicity and smoking status as the previous meta-analyses ([@b23-etm-04-04-0569],[@b24-etm-04-04-0569]), we conducted subgroup analyses involving gender and histology using the most appropriate genetic model.

Materials and methods
=====================

Search strategy
---------------

Pubmed, Embase and HuGENet databases were searched using the following terms or combinations: 'murine double minute 2', 'SNP309', '*MDM2*', 'polymorphism' and 'lung cancer'. The search was conducted until February 2012, and was limited to English language studies. To obtain additional potentially eligible studies we also reviewed the reference lists of the original studies identified, as well as reviews and previous meta-analyses.

Inclusion and exclusion criteria
--------------------------------

The eligible studies assessed in our meta-analysis had to achieve all of the following criteria: i) original studies concerning *MDM2* SNP309 polymorphism and lung cancer risk, ii) studies containing useful genotype distribution information, iii) case-control or cohort studies and iv) studies with a control population without prior or current severe respiratory disease and malignant disease. The exclusion criteria were: i) studies analyzing the same patient population (the most recent or complete study was chosen) and ii) case-only studies, which were studies without a healthy control group.

Data extraction
---------------

From each eligible study, we extracted data consisting of the first author, year of publication, ethnicity of the population, the genotype frequency of the cases and controls, diagnostic criteria and genotyping methods. For studies including the the frequency of genotypes of the cases and controls according to different subgroups for gender, histology and smoking status, data were separately extracted for each subgroup whenever possible.

Statistical analysis
--------------------

Hardy-Weinberg equilibrium (HWE) for the genotype distributions in the controls of each study was assessed using Pearson's Square (P≥0.05) ([@b28-etm-04-04-0569]). Cochran's Q test ([@b29-etm-04-04-0569]) and the inconsistency index (*I^2^*) ([@b30-etm-04-04-0569]) were next calculated for assessment of heterogeneity. We considered P\<0.05 and I^2^\>50% to indicate significant heterogeneity ([@b31-etm-04-04-0569],[@b32-etm-04-04-0569]). In this case, we checked the data and statistical methods again, and conducted sensitivity analysis or subgroup analysis to analyze the reasons for heterogeneity. If significant heterogeneity was present, the random-effects model was used, or else, the fixed-effect model was chosen. Next, logistic regression analysis was performed to examine the association between the *MDM2* SNP309 T\>G polymorphism and lung cancer risk. Three genetic models: dominant (GG/TG vs. TT), recessive (GG vs. TG/TT) and co-dominant (GG vs. TG and TG vs. TT) were used to evaluated the risk. The methodology used to determine the most appropriate genetic model was reported by Bagos and Nikolopoulos ([@b27-etm-04-04-0569]). Two parameters θ~2~ and θ~3~ were calculated using the formula: log it (π~ij~) = α~i~ + θ~2~ z~i2~+θ~3~ z~i3~ and OR~AB/AA~= exp(θ~2~), OR~BB/AA~= exp(θ~2~); where α~i~ are indicators of the study-specific fixed-effects, and θ~2~ and θ~3~ are dummy variables of genotypes AB and BB. The appropriate genetic model was identified using the following criteria ([@b33-etm-04-04-0569]): no association: θ~2~=θ~3~ (OR~AB/AA~ = OR~BB/AA~ = 1)dominant model: θ~2~≠0, θ~3~≠0 and θ~2~=θ~3~ (OR~AB/AA~ = OR~BB/AA~≠1)recessive model: θ~2~=0 (OR~AB/AA~ = 1) and θ~3~≠0 (OR~BB/AA~ ≠ 1)co-dominant model: θ~2~≠0, θ~3~≠0 and 2θ~2~=θ3 (OR^2^~AB/AA~ = OR~BB/AA~)

Finally, once the most approtriate genetic model was identified, it was used to again pool the results for both logistic regression analysis and heterogeneity assessment. Subgroup analysis also abided by this procedure.

Publication bias was assessed using Egger's tests and Begg's funnel plot ([@b34-etm-04-04-0569]). The statistical analysis was performed using METAGEN (<http://bioinformatics.biol.uoa.gr/~pbagos/metagen/>) and STATA version 11.1 (Stata Corporation, USA). All P-values were two-sided.

Results
=======

Study inclusion and characteristics
-----------------------------------

According to the inclusion and exclusion criteria, we extensively searched the Pubmed, Embase and HuGENet databases. There were 14 original studies relevant to the associated of *MDM2* SNP309 polymorphism and lung cancer risk retrieved. We reviewed all full-text studies intensively and excluded four studies without a control group ([@b35-etm-04-04-0569]--[@b38-etm-04-04-0569]). The study of Jun *et al* ([@b39-etm-04-04-0569]) was excluded since it included the same case and control population as Park *et al* ([@b17-etm-04-04-0569]). Finally, we excluded the study of Chua *et al* ([@b19-etm-04-04-0569]) since this study focused on the relevance between *MDM2* SNP309 and lung cancer risk among non-smoking women, while the other studies included no gender and smoking state restriction. Thus, eight case-control studies (6,696 lung cancer cases and 7,972 controls) concerning the associated of the *MDM2* SNP309 polymorphism and lung cancer risk were included in this meta-analysis ([@b9-etm-04-04-0569]--[@b11-etm-04-04-0569],[@b17-etm-04-04-0569],[@b18-etm-04-04-0569],[@b20-etm-04-04-0569]--[@b22-etm-04-04-0569]). The study of Pine *et al* ([@b11-etm-04-04-0569]) reported a population consisting of Caucasians and African-Americans, thus we recorded data on *MDM2* SNP309 genotype distributions, respectively.

All of the eligible studies were consistent with Hardy-Weinberg equilibrium. The characteristics of the studies are summarized in [Table I](#t1-etm-04-04-0569){ref-type="table"}, and frequencies of the *MDM2* 309T\>G polymorphism in the different populations are documented in [Table II](#t2-etm-04-04-0569){ref-type="table"}. Among these studies, some provided information on *MDM2* SNP309 genotype frequencies in different subgroups based on gender, histology and smoking status ([Table III](#t3-etm-04-04-0569){ref-type="table"}).

Meta-analysis results
---------------------

[Table IV](#t4-etm-04-04-0569){ref-type="table"} shows the detailed results of the heterogeneity test, assessment of the most appropriate genetic model, and the association between *MDM2* SNP309 T\>G polymorphism and lung cancer risk evaluated using odds ratios (ORs) with 95% confidence intervals (CIs). In the overall analysis, using the fixed-effect model, significant associations between the *MDM2* SNP309 polymorphism and lung cancer risk were observed in the recessive model (OR, 1.143; 95% CI, 1.047--1.247). Moreover, following the stratification of studies according to ethnicity, a statistically significant association was noted in Asian (OR, 1.260; 95% CI, 1.111--1.429) while not in European population. In the subgroup analysis based on gender, we found that the *MDM2* SNP309 GG genotype conferred a statistically significant increased risk of lung cancer development in females (OR, 1.282, 95%; CI, 1.062--1.548). However, we did not observe a similar result in males. In the subgroup analysis based on smoking status, a statistically significant association was observed in never smokers (OR, 1.328; 95% CI, 1.119--1.575) but not in the ever smoking group. However, there was no evidence of a statistically significant association between the *MDM2* SNP309 polymorphism and lung cancer risk in the subgroup analysis based on histology.

Publication bias
----------------

We performed Egger's test to access the publication bias. There was no indication that the shapes of the funnel plots exhibited obvious asymmetry, indicating any obvious evidence of publication bias in this meta-analysis.

Discussion
==========

Previous meta-analyses elucidating the link between the *MDM2* SNP309 polymorphism and lung cancer risk have provided discrepant results. Gui *et al* ([@b24-etm-04-04-0569]) found that the *MDM2* 309G allele is a low-penetrant risk factor for developing lung cancer in Asians, yet Bai *et al* ([@b23-etm-04-04-0569]) conducted a meta-analysis involved in the same research and found that the *MDM2* SNP309 GG genotype enhanced the risk of lung cancer development in never smokers with statistical significance, but no statistically significant was noted in Asian and European individuals. The main difference between these two meta-analyses was the genetic model selection. Hence, we conducted the present meta-analysis, one study more than these two meta-analyses ([@b23-etm-04-04-0569],[@b24-etm-04-04-0569]) using METAGEN. Apart from finding that the *MDM2* SNP309 polymorphism increases the risk of lung cancer development with a statistical significance, particularly in never smoking and Asian populations, we explored the relationships between the *MDM2* SNP309 polymorphism and the risk of lung cancer based on subgroups of different gender and histology using the most appropriate genetic model. We detected a statistically significant association between the *MDM2* SNP309 polymorphism and the risk of lung cancer in females.

According to the results of this meta-analysis, our main finding was that the *MDM2* SNP309 polymorphism was statistically significantly associated with the risk of lung cancer in females but not in males. It appears that the results of the subgroup analysis according to females and males was due to smoking and no smoking status as more men smoke than women, and it has been suggested that *MDM2* SNP309 increases the risk of lung cancer in never smokers ([@b21-etm-04-04-0569],[@b23-etm-04-04-0569],[@b40-etm-04-04-0569]). Yet, this assumption counteracts with the traditional view that tobacco smoking causes lung cancer. We prefer to believe that the estrogen receptor α (ERα) regulates *MDM2* SNP309 expression and leads to an increased risk of lung cancer in females. This indicates that men and women have approximately the same prevalence of lung cancer although smoking status tends to be higher among men compared to women.

The *MDM2* SNP309 G allele frequency was found to be a risk factor in Asians. This result is consistent with previous studies ([@b17-etm-04-04-0569],[@b18-etm-04-04-0569]). The possible cancerogenic mechanism of the *MDM2* SNP309 polymorphism was previously documented. However, the reason for the differential effects of the *MDM2* polymorphism according to ethnicity is unclear. The differences in environment and genetic backgrounds may influence the association between the *MDM2* SNP309 polymorphism and risk for lung cancer. Here, we must mention that, following subgroup analysis of Asian individuals, the result of our meta-analysis exhibited dissimilarity with Bai *et al* ([@b23-etm-04-04-0569]), which included the same studies conducted in Asians ([@b10-etm-04-04-0569],[@b17-etm-04-04-0569],[@b18-etm-04-04-0569]). The main reason is the selection of the genetic model. We identified the most appropriate genetic model using METAGEN as described by Bagos and Nikolopoulos ([@b27-etm-04-04-0569]) and this method allowed for heterogeneity between studies, thus our results should be more accurate.

Heterogeneity is inevitable in a meta-analysis ([@b41-etm-04-04-0569],[@b42-etm-04-04-0569]). We have to admit heterogeneity also existed between all the included studies in our meta-analysis. Sources of heterogeneity may come from various channels. First, studies included in this meta-analysis were distributed according to different ethnicity and environment. In addition, a different methodology including the source of controls, diagnostic criteria and genotyping methods may lead to heterogeneity.

Other possible limitations should be taken into account which contributed to the low statistical power of this meta-analysis. For instance, we only selected studies published in the electronic edition of the databases in English language and ignored the studies published in other languages, in paper version or not published at all. Publication bias may exist although Begg's funnel plot and Egger's test did not detect bias. Additionally, not all the included studies contained the complete data needed particularly for the subgroup analysis, thus we only analyzed the obtained data.

In conclusion, the current meta-analysis demonstrates that the *MDM2* SNP309 GG genotype may increase the risk of lung cancer particularly in Asians, females and never smoking population. Considering the limitations of this meta-analysis, further studies with large sample sizes, using well-designed and more accurate methods of genotyping are warranted to confirm the association between *MDM2* SNP309 and lung cancer risk.

This study was supported by the Guangxi Natural Science Foundation (grant no. 0991116).

###### 

Characteristics of all eligible studies included in this meta-analysis.

                                                                    Sample size   Diagnostic criteria                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  ---------------------------------------------- ------ ----------- ------------- --------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------- --------------------- -------
  Hu *et al* ([@b10-etm-04-04-0569])             2006   Asian       717           1,083                 Patients with histopathologically confirmed lung cancer.                                                                                                                                                                                                                                 Cancer-free controls were frequency-matched to the cases regardingage (65 years), gender and residential area (urban or countryside).                                                                                                                                                       PIRA-PCR      Population            0.832
  Li *et al* ([@b9-etm-04-04-0569])              2006   Caucasian   1,026         1,145                 Patients had newly diagnosed, histopathologically confirmed, previously untreated (i.e. by radiotherapy or chemotherapy) lung cancer without restrictions on age, gender, stage or histology.                                                                                            Controls were frequency-matched to the cases regarding age (±5 years), gender, ethnicity and smoking status (i.e. ever and never). Patients previously receiving radiotherapy or chemotherapy or recent (in last 6 months) blood transfusions or with previous cancer were excluded.        PIRA-PCR      Hospital              0.101
  Lind *et al* ([@b20-etm-04-04-0569])           2006   Caucasian   341           412                   Cases were newly diagnosed lung cancer patients treated by surgery. Tumor histology was confirmed by an experienced pathologist, and only NSCLC cases were included in the study.                                                                                                        Controls had a mean age of 59 years, smoked \>5 cigarettes/day, were current smokers or quit smoking for \<5 years prior to study.                                                                                                                                                          TaqMan        Population            0.059
  Park *et al* ([@b17-etm-04-04-0569])           2006   Asian       582           582                   Patients were newly diagnosed with primary lung cancer, and patients with a prior history of cancers were excluded.                                                                                                                                                                      Control subjects were randomly selected from a pool of healthy volunteers who visited the general health check-upcenter. They were frequency-matched (1:1) to the cases based on gender and age (±5 years).                                                                                 PCR-RFLP      Population            0.438
  Pine *et al* ([@b11-etm-04-04-0569])           2006   Caucasian   371           421                   All cases were histologically confirmed non-small cell primary tumors of the lungs. Patients were currently not taking antibiotics or steroid medications and had not previously undergone chemotherapy or radiation therapy (43).                                                       Hospital controls were cancer-free patients recruited from the same hospital as the cases and were frequency-matched to the cases by gender and ethnicity. Population controls were recruited from Baltimore City and the same counties to match cases by age, gender and ethnicity (43).   MGB Eclipse   Population Hospital   0.712
  Pine *et al* ([@b11-etm-04-04-0569])           2006   African     133           255                   All cases were histologically confirmed non-small cell primary tumors of the lungs. Patients were currently not taking antibiotics or steroid medications and had not previously undergone chemotherapy or radiation therapy (43).                                                       Hospital controls were cancer-free patients recruited from the same hospital as the cases and were frequency matched to the cases by gender and ethnicity. Population controls were recruited from Baltimore City and the same counties to match cases by age, gender and ethnicity (43).   MGB Eclipse   Population Hospital   0.252
  Zhang *et al* ([@b18-etm-04-04-0569])          2006   Asian       1,106         1,420                 Cases were newly diagnosed histopathologically confirmed lung cancer and patients were previously untreated with radio- or chemotherapy; no age, gender, tumor stage, or histology restrictions. Patients with previous cancer or metastasized cancer from other organs were excluded.   Cases had no individual history of cancer and the subjects were frequency-matched to the patients in terms of age (75 years) and gender.                                                                                                                                                    ARMS-PCR      Population            0.721
  Liu *et al* ([@b21-etm-04-04-0569])            2008   Caucasian   1,787         1,360                 Histologically confirmed lung cancer patients (≥ 18 years of age).                                                                                                                                                                                                                       Controls were recruited among healthy friends, non-blood related family members of cancer patients, or spouses and friends of cardiothoracic surgery patients. Potential controls that carried a previous diagnosis of malignancy (other than nonmelanoma skin cancer) were excluded.       TaqMan        Hospital              0.615
  Mittelstrass *et al* ([@b22-etm-04-04-0569])   2008   Caucasian   633           1,294                 Patients with an onset of disease at ≤50 years of age. Only newly diagnosed patients with histological or cytological confirmed primary lung cancer entered the study.                                                                                                                   Matched by gender and according to 3-year age groups to the cases in a 1:2 matching design                                                                                                                                                                                                  MALDI-TOF     Population            0.454

HWE, Hardy-Weinberg equilibrium.

###### 

Frequency of the *MDM2* 309T\>G polymorphism in the different populations.

                                                                           Cases   Controls                     
  ---------------------------------------------- ------ ------------------ ------- ---------- ----- ----- ----- -----
  Hu *et al* ([@b10-etm-04-04-0569])             2006   Asian              166     373        178   274   538   271
  Li *et al* ([@b9-etm-04-04-0569])              2006   Caucasian          419     472        135   408   573   164
  Lind *et al* ([@b20-etm-04-04-0569])           2006   Caucasian          130     156        55    161   207   44
  Park *et al* ([@b17-etm-04-04-0569])           2006   Asian              113     280        189   122   299   161
  Pine *et al* ([@b11-etm-04-04-0569])           2006   Caucasian          150     167        54    182   187   52
  Pine *et al* ([@b11-etm-04-04-0569])           2006   African-American   111     20         2     203   47    5
  Zhang *et al* ([@b18-etm-04-04-0569])          2006   Asian              249     561        296   418   711   291
  Liu *et al* ([@b21-etm-04-04-0569])            2008   Caucasian          702     802        283   530   631   199
  Mittelstrass *et al* ([@b22-etm-04-04-0569])   2008   Caucasian          270     293        70    547   598   149

###### 

Frequency of the *MDM2* 309T\>G polymorphism in the different subgroups.

                              Cases   Controls                           
  --------------------------- ------- ---------- ----- ----- ----- ----- ----------------------------------------------
  Gender                                                                 
    Females                   191     230        63    215   294   78    Li *et al* ([@b9-etm-04-04-0569])
    Males                     228     242        72    193   279   86    
    Females                   24      47         12    40    51    6     Lind *et al* ([@b20-etm-04-04-0569])
    Males                     106     109        43    121   156   38    
    Females                   11      40         28    22    62    31    Park *et al* ([@b17-etm-04-04-0569])
    Males                     19      62         45    100   237   130   
    Females                   346     381        139   302   362   91    Liu *et al* ([@b21-etm-04-04-0569])
    Males                     350     424        147   230   272   103   
    Females                   95      103        30    197   232   50    Mittelstrass *et al* ([@b22-etm-04-04-0569])
    Males                     175     190        40    350   366   99    
  Histology                                                              
    Adenocarcinoma            196     231        76    408   573   164   Li *et al* ([@b9-etm-04-04-0569])
    Squamous cell carcinoma   98      98         28    408   573   164   
    Adenocarcinoma            30      102        73    122   299   161   Park *et al* ([@b17-etm-04-04-0569])
    Squamous cell carcinoma   57      128        85    122   299   161   
    Adenocarcinoma            82      171        108   418   711   291   Zhang *et al* ([@b18-etm-04-04-0569])
    Squamous cell carcinoma   113     241        122   418   711   291   
    Adenocarcinoma            422     475        158   530   626   204   Liu *et al* ([@b21-etm-04-04-0569])
    Squamous cell carcinoma   178     186        59    530   626   204   
    Adenocarcinoma            98      98         25    547   598   149   Mittelstrass *et al* ([@b22-etm-04-04-0569])
    Non-small carcinoma       382     415        130   408   573   164   Li *et al* ([@b9-etm-04-04-0569])
    Small cell carcinoma      31      37         3     408   573   164   
    Non-small carcinoma       89      234        162   122   299   161   Park *et al* ([@b17-etm-04-04-0569])
    Small cell carcinoma      24      46         27    122   299   161   
    Non-small carcinoma       183     205        50    547   598   149   Mittelstrass *et al* ([@b22-etm-04-04-0569])
    Small cell carcinoma      70      67         16    547   598   149   
    Non-small carcinoma       130     156        55    161   207   44    Lind *et al* ([@b20-etm-04-04-0569])
    Non-small carcinoma       702     802        283   530   631   199   Liu *et al* ([@b21-etm-04-04-0569])
  Smoking status                                                         
    Ever                      357     385        112   332   482   146   Li *et al* ([@b9-etm-04-04-0569])
    Never                     62      87         23    76    91    18    
    Ever                      650     735        253   362   419   125   Liu *et al* ([@b21-etm-04-04-0569])
    Never                     52      67         30    195   212   74    
    Ever                      195     206        46    165   173   40    Mittelstrass *et al* ([@b22-etm-04-04-0569])
    Never                     71      77         21    369   413   105   
    Ever                      19      61         45    94    228   122   Park *et al* ([@b17-etm-04-04-0569])
    Never                     11      41         28    28    71    39    
    Ever                      172     338        182   255   377   141   Zhang *et al* ([@b18-etm-04-04-0569])
    Never                     77      223        114   193   334   150   

###### 

Meta-analysis of the *MDM2* SNP309 T\>G polymorphism in lung cancer.

  Group            OR~AB/AA~ (95% CI)     OR~BB/AA~ (95% CI)     Genetic model    OR (95% CI) of assumed genetic model   Heterogeneity check   
  ---------------- ---------------------- ---------------------- ---------------- -------------------------------------- --------------------- --------
  Total            1.003 (0.931--1.081)   1.144 (1.037--1.262)   Recessive        1.143 (1.047--1.247)                   0.056                 47.20%
    Caucasian      0.932 (0.850--1.022)   1.024 (0.896--1.170)   No association                                                                
    Asian          1.2 (1.050--1.372)     1.379 (1.142--1.665)   Dominant         1.260 (1.111--1.429)                   0.145                 48.30%
  Gender                                                                                                                                       
    Male           0.927 (0.817--1.053)   0.948 (0.796--1.131)   No association                                                                
    Female         0.939 (0.815--1.082)   1.239 (1.011--1.519)   Recessive        1.282 (1.062--1.548)                   0.336                 12.10%
  Histology                                                                                                                                    
    SCC            0.936 (0.779--1.124)   1.039 (0.796--1.358)   No association                                                                
    AC             0.991 (0.870--1.130)   1.204 (0.959--1.512)   No association                                                                
    SCLC           0.842 (0.653--1.086)   0.723 (0.501--1.043)   No association                                                                
    NSCLC          0.921 (0.838--1.014)   1.075 (0.944--1.225)   No association                                                                
  Smoking status                                                                                                                               
    Never          1.271 (1.063--1.521)   1.521 (1.214--1.905)   Dominant         1.328 (1.119--1.575)                   0.151                 40.50%
    Ever           1.013 (0.846--1.212)   1.2 (0.886--1.625)     No association                                                                

All ORs were derived from random-effects model if the heterogeneity was statistically significant, or else, from the fixed-effects model. Logistic regression analysis and heterogeneity check were performed using the same genetic model. AC, adenocarcinoma; SCC, squamous cell carcinoma; NSCLC, non-small carcinoma; SCLC, small cell carcinoma.
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